Premium
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues
Author(s) -
Span Paul N.,
Witjes Johannes A.,
Grebenchtchikov Nicolai,
GeurtsMoespot Anneke,
Moonen Paula M.J.,
Aalders Tilly W.,
Vriesema Jessica L.J.,
Kiemeney Lambertus A.L.M.,
Schalken Jack A.,
Sweep Fred C.G.J.
Publication year - 2008
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2008.07568.x
Subject(s) - plasminogen activator , urothelium , renal cell carcinoma , bladder cancer , kidney , urokinase , nephrectomy , pathology , tissue plasminogen activator , t plasminogen activator , urinary bladder , cancer , chemistry , transitional cell carcinoma , medicine
OBJECTIVE To analyse and compare the concentration of plasminogen activator (PA), urokinase‐type PA (uPA), tissue‐type PA (tPA), PA inhibitor (PAI)‐1 and PAI‐2, and the complexes uPA‐PAI‐1 and tPA‐PAI‐1 and calculated uPA and tPA uncomplexed with PAI‐1 (‘free’) in urothelial cell carcinoma and matched benign urothelium, and in renal cell carcinoma (RCC) and matched benign renal tissue. PATIENTS AND METHODS Tissue samples were obtained during cystectomy (33 patients) and nephrectomy (55), and specific enzyme‐linked immunosorbent assays were used to assess the PA components in extracts of these tissues. RESULTS Tissue levels of uPA‐PAI‐1 and tPA‐PAI‐1, but also PAI‐1 itself, were greater in tumorous bladder and kidney tissue than in matched normal tissue (by 1.5–7.8 times). Free tPA was clearly lower in tumour tissue (by 0–0.12‐fold). In bladder cancer, but not in RCC, levels of uPA (15.8‐fold) and free uPA (16.4‐fold) were greater in tumour tissue. Free uPA levels were less in RCC (0.41‐fold). For both normal bladder and kidney tissue, there was no clear correlation between uPA‐PAI‐1 complex and either component. However, the formation of tPA‐PAI‐1 complexes in normal bladder and kidney tissue was primarily determined by PAI‐1. Interestingly, in tumour tissues there was a strong, significant correlation between complex levels and both components. CONCLUSION RCC and bladder cancer show distinct profiles of components of the PA system. This study provides a basis for further studies into both the (patho)physiological role of the PA system in these tumours, and into a possible relation with tumour progression and prognosis, and as target for therapy.